CollabRx
CollabRx, Inc. (NASDAQ: CLRX) is a company that offers cloud-based expert systems for selecting clinical treatments for molecular diseases such as cancer. Its technology revolves around dynamically updated molecular disease models that form the basis of the expert systems. One of the challenges evolving from the recent explosion in biological information is to distill actionable clinically relevant therapy approaches from the vast amount of data available. The knowledgebases that inform the models are updated by a large network of advisors from academic and medical institutions.
CollabRx is a Delaware corporation, formed with the formerly named Tegal Corporation, which acquired the privately held company, also known as CollabRx, on July 12, 2012. On September 25, 2012, the stockholders amended the charter and assumed the “CollabRx, Inc.,” name. The former Tegal Corporation was formed in December 1989 to acquire the operations of a division of Motorola, Inc., that previously operated under the Tegal name. That company was founded in 1972, and acquired by Motorola, Inc., in 1978. The independent Tegal Corporation completed their initial public offering in October 1995.